Physician profile
Jiangping Liu
NPI 1518971027
$28,358.14
in general payments reported to CMS, 2019-2025
81 companies · $4,639 in 2025
The $4,639 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,706 · 2020: $3,027 · 2021: $3,751 · 2022: $3,934 · 2023: $3,838 · 2024: $4,463 · 2025: $4,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,863.26 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,567.81 | 2021-2025 | |
| Biogen, INC. | $1,980.15 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Sk Life Science, INC. | $1,980.13 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,631.55 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,465.39 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Amgen INC. | $1,409.12 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $1,281.45 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $1,186.37 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $972.34 | 2019-2022 | |
| Eisai INC. | $856.74 | 2019-2025 | |
| Pfizer INC. | $803.35 | 2022-2025 | |
| Genzyme Corporation | $800.62 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $687.95 | 2019-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $648.61 | 2019-2025 | Qelbree |
| Sumitomo Pharma America, INC. | $636.82 | 2023-2024 | Aptiom |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiangping Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.